Geluk A, Van Meijgaarden K E, Drijfhout J W, Ottenhoff T H
Department of Immunohematology and Blood Bank, University Hospital, Leiden, The Netherlands.
Mol Immunol. 1995 Sep;32(13):975-81. doi: 10.1016/0161-5890(95)00058-m.
The invariant chain (Ii) region that interacts with class II and inhibits premature peptide binding has been mapped to amino acids 82-107, known as CLIP. It is unclear whether CLIP binds directly to the class II peptide binding groove and thus competitively blocks binding of other peptides, or whether it binds to conserved class II sites and indirectly inhibits peptide binding by inducing conformational changes in class II. Here we show evidence that strongly suggests that CLIP binds within the peptide binding groove, as CLIP binds to various HLA-DR alleles using allele-dependent as well as allele-independent, methionine-based binding motifs. First, a core sequence of 12 amino acids was identified within CLIP which is required for optimal binding to DR1, DR2, DR3(17) and DR7. This sequence is composed of CLIP p88-99 (SKMRMATPLLMQ). By substitution analysis, all three methionine residues appeared to control CLIP binding to HLA-DR. However, whereas M90 controlled binding to all four alleles, M92 and M98 were of different importance for the various alleles: M92 is involved in CLIP binding to DR1 and DR3(17) but not to DR2 or DR7, and M98 controls CLIP binding to DR2, DR3(17) and DR7 but not DR1. Also, CLIP competes with known immunogenic peptides for class II binding in a manner indistinguishable from regular, class II binding competitor peptides. Finally, the dissociation rates of CLIP-class II complexed are similar to those of antigenic peptide-class II complexes. Thus, CLIP most likely binds to the class II peptide binding groove, since most allelic class II differences are clustered here. CLIP uses unconventional methionine anchor residues representing an allele-independent supermotif (M90) as well as allele-dependent motifs (M92 and M98).
与Ⅱ类分子相互作用并抑制肽过早结合的恒定链(Ii)区域已被定位到82 - 107位氨基酸,即CLIP。目前尚不清楚CLIP是直接结合到Ⅱ类肽结合槽并竞争性地阻断其他肽的结合,还是它结合到保守的Ⅱ类位点并通过诱导Ⅱ类分子构象变化间接抑制肽的结合。在这里,我们展示的证据强烈表明CLIP结合在肽结合槽内,因为CLIP使用基于甲硫氨酸的等位基因依赖性和非依赖性结合基序与各种HLA - DR等位基因结合。首先,在CLIP中鉴定出一个12个氨基酸的核心序列,这是与DR1、DR2、DR3(17)和DR7最佳结合所必需的。该序列由CLIP p88 - 99(SKMRMATPLLMQ)组成。通过替代分析,所有三个甲硫氨酸残基似乎都控制CLIP与HLA - DR的结合。然而,虽然M90控制与所有四个等位基因的结合,但M92和M98对不同等位基因的重要性不同:M92参与CLIP与DR1和DR3(17)的结合,但不参与与DR2或DR7的结合,而M98控制CLIP与DR2、DR3(17)和DR7的结合,但不参与与DR1的结合。此外,CLIP与已知的免疫原性肽竞争Ⅱ类分子结合的方式与常规的Ⅱ类分子结合竞争肽无法区分。最后,CLIP - Ⅱ类分子复合物的解离速率与抗原肽 - Ⅱ类分子复合物的解离速率相似。因此,CLIP很可能结合到Ⅱ类肽结合槽,因为大多数Ⅱ类等位基因差异都聚集在此处。CLIP使用代表非等位基因依赖性超基序(M90)以及等位基因依赖性基序(M92和M98)的非常规甲硫氨酸锚定残基。